NexImmune (NEXI): Company Future Sales Volume

Graphic logo of NexImmune (NEXI)

NexImmune, Inc. (NEXI) is liquidating its laboratories and returning capital to shareholders following the failure of clinical trials. Planned divestment volumes confirm this downturn, where the 0.00 mark serves as the current indicator. Previously, the business relied on robotic bioreactor control for drug scaling, while its monetization potential was based on developing immunotherapeutic cell activation methods for collaboration with pharma behemoths.

Company Revenue Forecast: NexImmune, Inc. (NEXI) for 07/04/2022 - 08/04/2024

NEXI (NexImmune, Inc.): analytical breakdowns and indicator data

- stock value and consensus price forecast:
- stock exchange capitalization data:
Summary company analysis:NexImmune
Product sample of NexImmune Corporation

NexImmune, Inc. (NEXI) is scaling its AIM nanotechnology platform to expand within the tumor immunotherapy sector. An analysis of the firm's sales volume expectations allows for an assessment of the resilience of future cash flows to market shocks. This metric aggregates the value of confirmed contracts and current shipments, measuring the speed of the business's adaptation to logistical disruptions. Rising values confirm a margin of safety, while a decline signals risks of profit shortfalls. The asset is classified as a high-risk speculative security.

Direct competitors

Company Projected Revenue ImmunityBio Inc (IBRX)|Company Future Sales Volume Immunocore PLC IMCR|Janux Therapeutics Inc - Company Future Sales Volume|Projected Sales Volume Arcus Corp RCUS|ZYME - Company Projected Revenue|TNGX (tangotx.com) - Company Revenue Forecast|Iovance Corp (IOVA) - Company Projected Revenue|Company Expected Sales Volume Immatics Corp (IMTX)|Company Future Sales Volume XNCR|CMPX - Company Sales Forecast|Company Future Sales Volume REPL (Replimune Corp)|Company Projected Revenue Volume LYEL|Projected Sales Volume IPHA (Innate Pharma)|Company Future Revenue PYXS|Compugen Limited - Projected Sales Volume|Company Expected Sales Volume IO Biotech Inc.|Sutro Biopharma, Inc. (STRO) - Company Projected Revenue|MiNK Therapeutics, Inc. - Company Future Revenue|HOWL (Werewolf) - Projected Sales Volume|Projected Sales Volume immixbio.com|Company Projected Revenue ALX Oncology Holdings (ALXO)|CUE - Company Expected Sales Volume|PDS Biotechnology Corporation - Company Future Sales Volume|Sonnet BioTherapeutics (SONN) - Company Expected Sales Volume|MAIA - Company Projected Revenue|LIMN: Company Projected Revenue|LVTX: Projected Sales Volume|Company Expected Sales Volume NextCure, Inc. (NXTC)|LPTX (Leap Tx) - Projected Sales Volume|INTS (Intensity Therapeutics) - Company Projected Revenue Volume|Company Projected Revenue Sensei Bio (SNSE)|TOVX (Theriva Biologics) - Company Future Revenue|Company Projected Revenue gritstonebio.com GRTS|Company Future Revenue KA|TSBX: Company Future Sales Volume|VCNX (Vaccinex, Inc.) - Company Revenue Forecast|Harpoon Tx (HARP) - Company Projected Revenue